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Abstract
Objective: The optimal treatment strategy for oropharyngeal squamous cell carcinoma is highly debated. However,
growing evidence supports the use of minimally invasive techniques, such as transoral laser microsurgery (TLM), as a
first-line treatment modality for these carcinomas. The purpose of our study was to assess the efficacy and safety of
TLM for the treatment of primary and recurrent oropharyngeal carcinomas.
Methods: All patients with oropharyngeal carcinoma undergoing TLM at the QEII Health Sciences Centre in Halifax,
Nova Scotia were identified within a prospective database monitoring TLM outcomes. Kaplan-Meier survival analysis was
used to evaluate the following end points at 36 months: local control (LC), disease-specific survival (DSS), and disease-
free survival (DFS). Safety endpoints included complications following surgery and long term morbidity related to TLM.
Results: Between 2003 and 2014, 39 patients with oropharyngeal carcinoma underwent TLM resection. Twenty-eight
(72 %) patients had primary carcinoma, nine (23 %) were radiation/chemoradiation (RT/CRT) failures, and two (5 %) had
second primaries following previous RT/CRT. Three patients had stage I disease, 8 stage II, 5 stage III, and 23 stage IV
disease. HPV status was available for 26 patients, of which 23 (88 %) had HPV positive disease. Kaplan-Meier estimates of
36-month LC, DSS, and DFS for primary oropharyngeal carcinomas were 85.5 % (SE 10.6 %), 85.7 % (SE 13.2 %) and
77.7 % (SE 12.5 %) respectively. Thirty-six-month outcomes for RT/CRT failures were 66.76 % (SE 15.7 %) for LC and 55.6 %
(SE 16.6 %) for DSS and DFS. Three patients developed complications following surgery.
Conclusions: Observed 36-month efficacy and safety outcomes support the use of TLM for the treatment of primary
and recurrent oropharyngeal carcinoma.
Keywords: Transoral laser microsurgery, Minimally invasive surgery, Oropharyngeal carcinoma, Head and neck surgery,
Head and neck cancer
Introduction
The incidence of oropharyngeal squamous cell carcinoma
(OSCC) has been increasing, largely because of increasing
rates of Human Papilloma Virus (HPV) infection [1–4].
This is an important trend clinically as HPV positive OSCC
is associated with a better prognosis and treatment outcome
[5, 6]. In the past, the management of OSCC has largely
been guided by treatments that minimized functional mor-
bidities. Radiation/chemoradiation (RT/CRT) was often
preferred because historically, surgical intervention involved
open en bloc resection of the tumour with free flap recon-
struction, resulting in significant compromise of surround-
ing structures and ultimately function. However, RT/CRT
has been associated with significant acute and long term
toxicities and decreased quality of life [7–10].
More recently, transoral laser microsurgery (TLM) has
emerged as a minimally invasive, endoscopic surgical
technique for the management of oropharyngeal and
laryngeal carcinomas. Initially used for carefully selected
early stage head and neck cancers, experience with TLM
has expanded its use to include select advanced lesions
[11, 12]. Contraindications to TLM include inadequate
access to the primary site (e.g. trismus, large tongue base,
prominent dentition, etc.), large vessel proximity or
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involvement (e.g. tumour adjacent to the carotid bulb or
internal carotid, deep bilateral base of tongue invasion in-
creasing the risk of damage to both lingual arteries, etc.),
and oncologic contraindications including T4b cancers,
unresectable neck disease or multiple distant metastases
[13, 14]. Despite these limitations, TLM offers potential
advantages over open surgery including shorter recovery
time, fewer complications and better functional outcomes
[15–17]. Similarly, preliminary studies have demonstrated
TLM to have improved functional outcomes compared to
RT/CRT, particularly with respect to swallowing function
[18, 19]. Surgical intervention also offers the advantage of
pathologic characterization of the tumour, helping to
guide further management and treatment, an advantage
that is not readily available with RT/CRT.
The purpose of this study was to evaluate the onco-
logic measures of TLM for OSCC at our center, adding
to the growing evidence of support for the use of TLM
as a first line treatment modality for these carcinomas.
Methods
This was a prospective, cohort study based on a database
monitoring all malignancies treated with TLM at the QEII
Health Sciences Centre in Halifax, Nova Scotia. The collec-
tion of information within the database was approved by
our institutional research ethics board. The database was
created in 2005 and has been prospectively maintained since
that time. Information prior to 2005 was collected retro-
spectively at the time of the creation of the database. Details
regarding data collection and the information contained
within the database have been described previously [20, 21].
Between January 2002 and December 2014, approxi-
mately 300 different patients with suspected upper aero-
digestive tract malignancies were treated with TLM by
the senior author at our centre. All cases of primary or
recurrent OSCC treated with TLM were included in the
current study. Exclusion criteria included malignancies
in all other sites of the upper aerodigestive tract treated
with TLM.
TLM, neck dissection and adjuvant therapy
All patients in the cohort underwent TLM resection. At
the time of resection, a FK Retractor and/or Bouchayer
laryngoscope was used to obtain adequate tumour ex-
posure. Once adequate exposure was obtained, tumours
were excised with a CO2 laser using a tumour-splitting
approach. Margin status was determined at the time of
surgery through frozen section analysis. Positive frozen
margins were subsequently resected until negative mar-
gins were obtained. Following surgery, tissue submitted
for intraoperative margin analysis was resubmitted for
routine processing. The main resection specimen was
also submitted in toto for pathological characterization
of the tumor.
Neck dissections were done concurrently at the time
of TLM resection. In keeping with current guidelines, all
patients were considered for concurrent neck dissections
unless they had previous radiation failure or had no evi-
dence of clinical or radiologic neck disease [22]. The ex-
ception were patients who had previous radiation failure,
but stopped radiation early because of side-effects or
presented with new or recurrent neck disease for which
a neck dissection was not previously done. Patients with
primary tonsil carcinoma underwent ipsilateral neck dis-
sections while patients with base of tongue carcinomas
underwent bilateral neck dissections. External carotid
branches were ligated at the time of the neck dissection,
including ligation of lingual and facial arteries.
Adjuvant therapy was offered to patients who met one
or more of the following criteria, unless there was a
contraindication to therapy: advanced disease, multiple
nodal involvement, extracapsular extension from involved
lymph nodes, perineural invasion, or positive margins
following TLM resection. This is in keeping with current
evidence that demonstrates improved survival with adju-
vant therapy in these select patients [22–25].
Analysis
A descriptive analysis of demographics, morbidities, and
outcomes was performed. HPV status was determined
by p16 immunohistochemistry. HPV positive disease
was defined by strong, diffuse nuclear and cytoplasmic
positivity (>70 %) of tumor cells for the p16 marker.
Smoking status was self-reported by patients and catego-
rized into current, past or non-smoking status at the
time of surgery. Margin status was determined by
reviewing individual pathology reports for all patients in
the cohort. Close margins were defined as any margin
less than 5 mm.
All statistical testing was performed using an
intention-to-treat analysis. Kaplan-Meier 36-month sur-
vival analysis was performed for the following end
points: local control (LC), disease-free survival (DFS),
and disease-specific survival (DSS). Local control was
defined as local recurrence-free survival obtained with
one TLM resection or with subsequent reresection(s) for
positive or close margins. Disease-free survival was de-
fined as no local or regional recurrence or presence of a
new second primary oropharyngeal tumour. Cancers
were defined as a second primary tumour if they oc-
curred more than 5 years after the last received treat-
ment or if they occurred on the contralateral side to a
previously treated unilateral tumour that did not cross
the midline.
Results
Between 2002 and 2014, 39 patients (31 males and 8
females) with oropharyngeal carcinoma underwent TLM
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resection (Table 1). The mean age of the cohort at the
time of diagnosis was 59.6 years (range 32–80). Twenty-
eight (72 %) patients had primary carcinoma, 9 (23 %)
were RT/CRT failures, and 2 (5 %) had second primaries
following previous RT/CRT. Three patients had stage I
disease, 8 stage II, 5 stage III, and 23 stage IV. HPV sta-
tus was available for 26 patients, of which 23 (88 %) had
HPV positive disease. The mean time of follow-up was
23 months. Among patients with primary OSCC, 21
patients received adjuvant therapy; 14 received radiation
therapy and seven received chemoradiation. Twenty-nine
(75 %) patients underwent concurrent neck dissections at
the time of TLM resection. The average length of hospital
stay was 3.8 days (range 2–10 days).
Three patients developed complications following
TLM resection. One patient experienced significant
postoperative bleeding requiring a blood transfusion
14 days postoperatively. The patient was taken to the
OR for exploration, but no active site of bleeding could
be identified. The bleeding resolved spontaneously and
was later determined to be caused from a longstanding
gastric ulcer. Two patients developed cardiovascular
complications. One patient experienced a myocardial in-
farction following TLM reresection of a positive margin
and another patient developed a pulmonary embolism
3 days postoperatively. All patients recovered from their
complications.
Two patients required a gastrostomy tube (G-tube)
postoperatively following initial TLM resection. One
patient required a temporary G-tube (<2 months) fol-
lowing TLM resection for swallowing difficulties. The
other patient required a long-term G-tube following
postoperative CRT for a close margin. One and two year
G-tube rates following initial TLM resection were 3 and
0 %, respectively. Three patients required G-tubes fol-
lowing salvage therapy for recurrences. One patient
required a temporary G-tube (<6 months) following sal-
vage radiation therapy for a local recurrence. Another
patient, who underwent a radical neck dissection follow-
ing recurrence of a neck mass, subsequently developed a
hematoma postoperatively and required a tracheostomy
and G-tube for breathing and swallowing difficulties.
Finally, one patient who ultimately underwent a total
laryngopharyngectomy for new primary disease, required
a G-tube postoperatively after the development of a tra-
cheoesophageal fistula. Of note, one patient developed
mild velopharyngeal insufficiency postoperatively that
improved overtime without intervention and another
patient, who was a previous CRT failure with a preopera-
tive G-tube, was able to have their G-tube successfully
removed following TLM resection.
Five patients had temporary tracheostomies following
TLM. Initially, this was done for all TLM resections for
anticipated postoperative swelling. This practice was
stopped after it was seen that most patients had minimal
swelling postoperatively. All five patients had their
tracheostomies removed prior to discharge. One and
two year tracheostomy rates were 0 %.
There were eight cases of recurrence following TLM,
including five local recurrences (two of which also had
regional recurrence), two regional recurrences, and one
case of metastasis. There was also one case of a new pri-
mary in a patient with a right tonsil OSCC who went on
to develop a left piriform sinus OSCC following TLM.
Recurrence was more common among RT/CRT failures
compared to patients with new primary oropharyngeal
Table 1 Patient characteristics (n = 39)
Characteristic Number of patients (%)
Age, y
Mean (Range) 59.6 (32–80)
Sex
Male 31 (79.5 %)
Female 8 (20.5 %)
Tumour subsite
Base of tongue 20 (51 %)
Tonsil 19 (49 %)
Stage
I 3 (7.5 %)
II 8 (20.5 %)
III 5 (13 %)
IV 23 (59 %)
T Stage
T1 9 (23 %)
T2 23 (59 %)
T3 7 (18 %)
T4 0 (0 %)
N stage
N0 13 (33 %)
N1 3 (8 %)
N2a 5 (13 %)
N2b 13 (33 %)
N2c 2 (5 %)
N3 3 (8 %)
HPV status (n = 26)
Positive 23 (88.5 %)
Negative 3 (11.5 %)
Smoking status (n = 37)
Current smoker 6 (16 %)
Past smoker 20 (54 %)
Lifetime nonsmoker 11 (30 %)
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carcinoma. Kaplan-Meier estimates of 36-month LC for
new primary oropharyngeal carcinoma was 85.5 % (SE
10.6 %) compared to 66.76 % (SE 15.7 %) for RT/CRT
failures (Fig. 1).
During follow-up, seven patients died from their
disease. All four RT/CRT failures who developed re-
currence died from their disease. Two of four patients
with primary oropharyngeal carcinoma who developed
recurrence died from their disease. One patient, who
received TLM for a second primary following previ-
ous CRT, developed a new primary following TLM
and despite undergoing a total laryngopharyngectomy,
ultimately developed metastatic disease and died from
their disease. Kaplan-Meier estimates of 36-month
DSS and DFS for primary oropharyngeal carcinoma
were 85.7 % (SE 13.2 %) and 77.7 % (SE 12.5 %) com-
pared to 55.6 % (SE 16.6 %) and 55.6 % (SE 16.6 %)
for RT/CRT failures (Fig. 2).
Adjuvant therapy was administered to 21 of 28
patients with new primary OSCC (Table 2). Fourteen
patients received radiation therapy and seven received
chemoradiation. The remaining seven patients received
no postoperative therapy. Among patients who did not
receive postoperative therapy, three developed recur-
rence. All three patients had stage III/IV oropharyngeal
carcinoma and of these, two patients refused adjuvant
therapy for personal reasons and one was not a candi-
date because of comorbid health conditions. No patients
with stage I/II disease treated with TLM monotherapy
developed recurrence. Among patients who received ad-
juvant therapy, one patient developed metastatic disease.
Salvage therapy was carried out in two of four cases of
recurrence among patients with primary oropharyngeal
carcinoma. One case of local recurrence was salvaged
with radiation therapy and the patient currently remains
disease free. The other case of regional recurrence was
salvaged with a selective neck dissection, but unfortu-
nately the patient went on to develop metastatic disease
and died from their disease. Among the other two cases
of recurrence, one patient developed metastatic disease
for which further therapy was not indicated and the
other patient refused further treatment after local recur-
rence. As previously mentioned, a total laryngopharyn-
gectomy was carried out in a patient who developed a
new primary following TLM, but the patient ultimately
developed metastatic disease and died from their disease.
No previous RT/CRT failures who developed recurrence
received salvage therapy.
Four patients (10 %) had positive margins and one pa-
tient (3 %) had a close margin at the primary site follow-
ing initial TLM resection (Table 3). Four patients,
including the patient who had a close margin, had pri-
mary OSCCs and one patient was a previous RT failure.
The previous RT failure subsequently underwent TLM
reresection, but ultimately developed locoregional recur-
rence and died from their disease. Among the four pa-
tients with primary OSCCs, three received postoperative
chemoradiation and one received postoperative radi-
ation. Two of the three patients who received postopera-
tive chemoradiation stopped their chemotherapy early
because of side-effects. Of the patients who received ad-
juvant therapy, one developed metastatic disease and
died from their disease. The other three patients remain
disease free.
Twenty three patients had HPV positive disease and
three patients had HPV negative disease. HPV status
could not be determined in 13 patients. Among HPV
positive patients, two developed recurrence. One patient
Fig. 1 Kaplan-Meier estimates of 36-month local control
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developed a local recurrence after initially refusing adju-
vant radiation therapy and is currently awaiting further
management. The other patient developed metastatic
disease and died from their disease. Among the three pa-
tients with HPV negative disease, two developed recur-
rence. One patient developed recurrent regional disease
and died from their disease. The other patient developed
local recurrence and after receiving salvage radiation
therapy, remains disease free.
Discussion
Increasing evidence supports the use of transoral surgery
as an effective, minimally invasive strategy for the treat-
ment of OSCC. Currently, two transoral treatment modal-
ities exist, TLM and transoral robotic surgery (TORS).
Both transoral approaches have demonstrated excellent
local control and overall survival for the treatment of pri-
mary OSCC, while minimizing functional compromise
[11, 26–28]. Recent studies have also demonstrated TLM
Fig. 2 Kaplan-Meier estimates of 36-month disease specific survival and disease free survival
Table 2 Adjuvant therapy for new primary OSCC following TLM resection (n = 28)
Adjunctive therapy Number Recurrence New primary Recurrence type Laryngectomy Death due to disease
None 7 3 0 2 Local 0 1
1 Regional
Radiation 14 0 0 0 0 0
Chemoradiation 7 1 0 1 Metastatic 0 1
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and TORS to be effective as salvage therapy for recur-
rences in previous RT/CRT failures [29, 30]. This current
study adds to the growing body of evidence, demonstrat-
ing TLM to have high rates of local control and overall
survival for both primary and recurrent oropharyngeal
cancers with excellent functional outcomes.
Eight patients in the cohort developed recurrence.
This relatively high rate of recurrence can be expected
based on the increased risk of recurrence among RT/
CRT failures, which has been previously demonstrated
to have a worse prognosis [31, 32]. Among the nine RT/
CRT failures in the study, four developed recurrence.
Despite these findings, TLM still demonstrated good
local control and overall survival for RT/CRT failures
when compared to other available salvage treatment
modalities [31, 32].
Among patients with primary OSCC, recurrence was
higher in patients who did not receive adjuvant therapy.
This can be partly explained by the high rate of recur-
rence among patients with advanced disease who refused
adjuvant therapy. In the current cohort, all three patients
with advanced primary disease who did not receive
adjuvant therapy following TLM, either because they
refused or were not a candidate for RT/CRT, developed
recurrence. There was no recurrence in patients with
stage I/II primary disease who received TLM monother-
apy. This is consistent with previous studies that have
demonstrated TLM to be effective as a single treatment
modality for early disease [33]. Although it is difficult to
draw conclusions from small numbers, this study provides
further evidence for the benefit of TLM as a single treat-
ment modality for early disease and the potential benefit
of postoperative adjuvant therapy in select patients with
advanced disease.
In the current cohort, 4 patients had positive margins
(10 %) and one patient (3 %) had a close margin at the
primary site following initial TLM resection. This is
comparable to other studies, which have demonstrated
positive margin rates to be between 15 and 30 % [34].
Similar to the findings in other studies, patients with
positive margins in the current cohort tended to have
bulkier tumours (T2 or T3) and node positive disease
[34]. One of the major advantages of TLM over other
treatment modalities is the ability to perform reresection
in the presence of positive margins. This is particularly
beneficial for patients with previous RT/CRT failure, as
treatment modalities for OSCC recurrence is limited. In
the present study, only one patient with a positive mar-
gin underwent reresection. Unfortunately, the patient
subsequently developed locoregional disease and died
from their disease. The other three patients who had
positive margins and one patient who had a close margin
following initial TLM resection would also generally be
considered for reresection. However, all four patients
had advanced diseased and required postoperative adju-
vant therapy. As pathology reports at our centre gener-
ally take several weeks to obtain, it was decided that RT/
CRT should be initiated before final pathology results
were obtained. This proved to be an effective approach
as three of the four patients with positive/close margins
who received adjuvant therapy currently remain disease
free. However, in early disease TLM reresection alone
could be considered, helping to avoid the acute and long
term complications related to RT/CRT.
Previous studies have demonstrated HPV positive
OSCCs to have a better prognosis and treatment out-
come compared to HPV negative disease [5, 6]. This
trend was reflected in our study where only 9 % (2/23)
of patients with HPV positive disease developed a recur-
rence compared to 66 % (2/3) of patients with HPV
negative disease. Unfortunately, status was unknown for
13 patients as p16 immunohistochemistry was only in-
troduced and done routinely at our centre for OSCCs
since 2009. Obviously with such a small number of HPV
negative patients in our study, it is difficult to draw
meaningful conclusions. However, the study does dem-
onstrate TLM to be highly effective for the management
of HPV positive disease.
One of the limitations of our study is the relatively
limited period of follow-up for a large percentage of
the cohort. Although the cohort included all patients
undergoing TLM between 2002 and 2014, more than
half of the patients underwent initial TLM resection
from 2012 onward. As a result, statistical analysis was
only adequately powered for follow-up at 3 years.
Despite this limitation, the current study provides
compelling evidence for the efficacy and safety of
TLM for primary and recurrent OSCCs.
Conclusion
The optimal treatment strategy for oropharyngeal carcin-
oma is highly debated. However, growing evidence sup-
ports the use of TLM as a safe and effective first-line
treatment modality for OSCCs. This study provides fur-
ther evidence for the use of TLM as a first-line treatment
modality for primary and recurrent OSCCs, demonstrat-
ing excellent 3-year survival and functional outcomes.
Table 3 Intraoperative disease control
Margins (−) Margins (+)
Total 34 5




New primary 1 0
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